Floatz logo

Cngrc Peptide-Tnf Alpha Conjugate

Head and Neck Cancer

European Organisation for Research and Treatment of Cancer - EORTCunclassifiedPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

142 Active assets in the Head and Neck Cancer cohort.

Asset / SponsorPhaseRating
NEPENTHE
Instituto Nacional de Cancer, Brazil
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
LIDOCAINE
Instituto Nacional de Cancer, Brazil
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
FILGRASTIM
University of Colorado, Denver
Phase 2BB

View all 50 →

Same molecule, other indications

Cngrc Peptide-Tnf Alpha Conjugate is also rated in:

cancer of unknown primary siteDormant
CC
Indicative ·
46 / 100
View asset →
kidney cancerDormant
CC
Indicative ·
42 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →